Pay in 4 interest-free payments of $5.51 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
With cautious administration and awareness of the risks, patients can make informed decisions about IV NAD therapy's place in their personal healthcare journey
Cell Death Dis 12(10):917
Current Research Status and Future Directions Where We Are Now (2026) Retatrutide is currently in Phase 3 clinical development under Eli Lilly's TRIUMPH program, which includes multiple trials: TRIUMPH-3 Obesity without type 2 diabetes Evaluating 12mg vs 9mg vs placebo in adults with BMI 30 or 27 with comorbidities TRIUMPH-4 Obesity with type 2 diabetes Testing efficacy and safety in patients with both conditions (preliminary: 28.7% weight loss) MASLD/NASH Trials Metabolic dysfunction-associated steatotic liver disease Leveraging glucagon's liver fat reduction effects Cardiovascular Outcomes Long-term CV safety and benefits Following precedent of STEP and SURMOUNT trials for GLP-1 drugs Timeline to FDA Approval 2023: Phase 2 results published (NEJM) 2024-2026: Phase 3 trials ongoing (TRIUMPH program) 2026-2027: Anticipated FDA submission (if trials successful) 2027-2028: Potential FDA approval and commercial launch What Researchers Are Watching The main questions Phase 3 needs to answer: Long-term efficacy: Does weight loss plateau or continue beyond 48 weeks
Clinical studies and patient experiences show different rates of weight loss, often depending on individual factors like baseline weight, diet, exercise, and adherence to the medication regimen
US$ 28.30
US$ 21.53
US$ 27.49
US$ 22.36
US$ 23.13
US$ 26.76
